ERBB2 and breast cancer: Fujii et al. constructed a nomogram to predict pCR in HER2+ breast cancer treated with NCT regimens containing trastuzumab;12 however, the C-index of the nomogram was only 0.69 and they did not have an independent cohort to validate the nomogram.